Effect of therapeutic targeting of xCT on USP15/SMAD-driven gemcitabine resistance in KRAS-mutant pancreatic cancer. TNTD and OS in a validation cohort composed of data from two prospective studies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results